INTRODUCTION
A key theme in regenerative medicine is repair of damaged tissue with treatment using stem/ progenitor cells. For example, bone defects can be treated with stem/progenitor cells isolated from bone marrow [1] and adipose tissue [2] . However, the processes of isolating these stem/ progenitor cells, such as bone marrow aspiration and liposuction, are invasive. Cells that have similar regenerative function and can be isolated with minimal or no invasive procedure will greatly simplify the bone healing process. Peripheral blood is an ideal alternative source for these cells owing to the ease of cell retrieval and blood bank storage. Peripheral blood is also known to host many stem/progenitor cells, such as peripheral blood stem cells, which are used in bone marrow transplantation therapy [3] , and endothelial progenitor cells, which have long been recognized to participate in new blood vessel formation [4] . A frequently discussed cell is the mesenchymal stem cell (MSC), which is a multipotent stromal cell with prominent regenerative functions. The MSC is an ideal candidate for many cell-based therapies, including enhanced healing of bone defects [1, 5, 6] . MSCs have been isolated from various tissues [7, 8] , including bone marrow, fat, and muscle. However, the existence of MSCs in the peripheral blood has not been confirmed (as described in the Discussion) [9] [10] [11] .
Cells cultured from peripheral blood have been hypothesized to be able to enhance bone healing. For example, fibrocytes [12] and monocyte-derived mesenchymal progenitor cells [13] are capable of in vitro calcification in response to differentiation signals. Moreover, circulating skeletal stem cells [14] and circulating osteoblasts [15] are capable of bone formation when placed in subcutaneous pockets of animals. Only one study has shown circulating cells to have enhancement of bone healing in vivo. In that study, an undefined MSC-like population was shown to improve healing in the rabbit ulna [16] . However, the identity of the MSC-like cells was not clear (discussed further in the Discussion).
In the present study, we define a population of cells derived from the peripheral blood that can heal critical-sized bone defects. Unlike previous studies investigating cell-based therapy to enhance long bone healing through endochondral ossification [16] , we investigated and defined a cell population that can enhance healing of calvarial bone defects through intramembranous ossification. In isolating the cells responsible for the healing process, we discovered a population of nonhematopoietic cells that fulfill the MSC criteria, as defined by the International Society for Cellular Therapy (ISCT). We have named these cells "bloodderived mesenchymal stem cells" (BD-MSCs).
MATERIALS AND METHODS

Peripheral Blood Collection and Heavy Fraction Cellular Isolation
All experiments were performed in accordance with the Stanford University Animal Care and Use Committee guidelines (protocol identification [ID] no. 11048). The peripheral blood was collected from male FVB-L2G, FVB-luciferase (Luc)-green fluorescent protein (GFP), or FVB mice (Jackson Laboratory, Sacramento, CA, http://www/jax.org) or CD-1 mice (Charles River Laboratories International, Inc., Wilmington, MA, http://www.criver.com) at the age of 7 to 8 weeks, depending on the experimental design. Among them, only cells from FVB-L2G mice exhibit strong green fluorescence that can be detected with fluorescence microscopy. To collect peripheral blood, the mice were anesthetized with isoflurane (Butler Schein Animal Health, Encinitas, CA, https://www. henryscheinvet.com) and injected with 4 U of heparin (SigmaAldrich, St. Louis, MO, http://www.sigmaaldrich.com) through retro-orbital veins. After 5 minutes, the mice were bled from the retro-orbital vein, and the blood was collected into a 1.5-ml microcentrifuge tube containing 1 U of heparin in 100 ml of phosphatebuffered saline (PBS; Life Technologies, Carlsbad, CA, http:// www.lifetechnologies.com). The blood collected from each mouse was 1 to 1.3 ml routinely. To lyse red blood cells, 3 ml of blood was mixed with 30 ml of red blood cell lysis buffer (NH 4 Cl 8.3 g/liter, KHCO 3 1 g/liter, EDTA 3.7 g/liter). The mixture was immediately subjected to centrifugation at 400g for 15 minutes at 20°C, and the pellets were collected. The pellets, which contained the remaining nucleated cells and debris, were resuspended in 3 ml of PBS, laid on top of a density barrier (density is 1.063), and subjected to centrifugation (360g for 15 minutes at 20°C), as diagramed in Figure 1A . This barrier was prepared by mixing 1 ml OptiPrep (Sigma-Aldrich) with 4.4 ml of PBS. The resulting pellet, a collection of nucleated cells with density greater than 1.063, was resuspended in complete medium (a-minimal essential medium [MEM] with 20% fetal bovine serum [FBS], 13 antibioticantimycotic, 20 mg/liter gentamicin; all from Life Technologies) to produce the heavy fraction (HF) (Fig. 1) .
Coculture System
The HF suspension was seeded on a Transwell insert (Corning, Corning, NY, http://www.corning.com) at a density of 1-1.5 3 10 5 cells per cm 2 in 1 ml of complete medium. The feeder cells were immortalized mouse hepatic, AML12 cells [17] that had been treated with mitomycin C (MMC) (Sigma-Aldrich), following the manufacturer's instructions. In brief, monolayers of AML12 cells were incubated with the complete medium containing MMC at a final concentration of 30 mg/ml. After 2 hours of incubation, the AML12 cells were washed twice with PBS, detached with trypsin-EDTA (0.5%), and resuspended in the complete medium. MMC-treated AML12 cells were then seeded on the polystyrene surface underneath the Transwell insert at a density of 5 3 10 4 cells per cm 2 in 2 ml of complete medium. The HF cells and MMC-treated AML12 cells were separated by a polyester membrane (0.4 mm diameter pore size). No mixing of cells was observed during the course of our experiment. The coculture system was incubated at 37°C in a humidified CO 2 (5%) incubator. The medium was changed every 3 days, and the resultant cells on the Transwell inserts were harvested in 3-5 weeks. The cells produced in the Transwell membrane without further passage on tissue culture dishes were defined as at passage 0.
Flow Cytometry
To analyze the surface markers on the cells on the Transwell inserts, the cells were detached from the membrane using Accutase (Innovative Cell Technologies, San Diego, CA, http://www. accutase.com), resuspended in the complete medium, stained with fluorophore-conjugated monoclonal antibodies, and subjected to analysis using the BD LSRII analyzer (BD Biosciences, San Jose, CA, http://www.bdbiosciences.com). The antibodies used were anti-CD45/APC, anti-stem cell antigen 1 (Sca-1)/APCCy7, anti-lineage (Lin)/Pacific Blue, anti-c-kit/Pacific Blue, antic-kit/phycoerythrin (PE)-Cy7, anti-CD73/PE, anti-CD44/Alexa Fluor 700, anti-CD105/Pacific Blue, anti-CD105/Alexa Fluor 488, anti-CD140a/PE, anti-CD29/Pacific Blue, anti-CD90.1/PE, anti-CD90.1/PerCp-cy5.5, anti-CD19/Alexa Fluor 700, anti-CD14/PECy7, anti-CD34/PE/Cy5 (purchased from BioLegend, San Diego, CA, http://www.biolegend.com), and anti-CD34/Alexa Fluor 700 (eBioscience Inc., San Diego, CA, http://www.ebioscience.com).
Purification of CD45
2 Cells Grown in the Coculture System
The CD45
2 subset of cells was purified by successive cell passages and magnetic-activated cell sorting (MACS). CD45 2 cells were found to detach relatively quickly from the Transwell membranes and culture dishes compared with CD45 + cells. Highly enriched (up to 80% purity, as judged using flow cytometry) CD45 2 cells
were obtained with a single passage. The resultant population of enriched CD45 2 cells was further subjected to depletion of CD45 + cells using MACS MicroBead Technology (Miltenyi Biotec, San Diego, CA, http://www.miltenyibiotec.com). In brief, the cells were mixed with rat anti-mouse anti-CD45 (500 mg/ml) at a volume ratio of 1:100 in complete medium. After 40 minutes of incubation at 4°C with gentle rotation, the unbound anti-CD45 was removed by centrifugation, and goat anti-rat IgG MicroBeads were applied and incubated for another 40 minutes. The resultant cultures were passed through an LS column to deplete the CD45 + cells, in accordance with the manufacturer's instructions, except that complete medium was used throughout. The flow through was cycled back to the column 5 times before obtaining the final flow through, which contained the CD45 2 cells. This process led to a high cell survival rate and near homogeneity of CD45 2 cells, determined using a live cell immunofluorescence assay. This cell population of purified CD45 2 cells was used for additional experiments.
Live Cell Immunofluorescence
To investigate the cell surface marker expression of living purified CD45 2 cells, 5,000 cells in 100 ml of complete medium were seeded per well in a 96-well plate (Corning) and incubated in a humidified CO 2 incubator. After 48 hours, the medium was replaced with 50 ml of fresh culture medium containing the primary antibody at the concentration of 5 mg/ml, and the culture plate was returned to the incubator. All primary antibodies were purchased from BioLegend. Except for anti-CD29 and anti-CD90.1, all antibodies were rat-produced. Anti-CD29 was produced from the Armenian hamster and was conjugated with biotin. Anti-CD90.1 was produced from the mouse. After 40 minutes, the medium containing the primary antibody was removed. The cells were washed twice with fresh medium and were further incubated in 50 ml of fresh medium containing 4 mg/ml goat anti-rat 
Osteogenic Differentiation Assay
Cells at 2-7 3 10 4 per well were seeded to a 2-cm 2 polystyrene well (Corning). After 48 hours, the cells were subjected to osteoblast differentiation medium (ODM; a-MEM containing 10% FBS, 13 penicillin-streptomycin, 0.1 mM dexamethasone, 10 mM b-glycerol phosphate, and 50 mM ascorbic acid) [18, 19] . The cells were cultured in ODM for 14 days, with medium changes every 2 days. Alizarin red S (Sigma-Aldrich) was used to stain the accumulated calcium deposits. In brief, the cells were fixed with 10% neutral buffered formalin, stained with alizarin red staining solution (0.2% alizarin red in deionized H 2 O with pH adjusted by 15 N ammonium hydroxide to 6.4) for 30 minutes at room temperature, and washed 3 times with PBS before microscopy. For quantitative measurement of calcium deposition, duplicate experiments were performed, in which alizarin red S was extracted with 1 ml of solution containing 20% methanol and 10% acetic acid. The resulting clear yellow solution was quantitated by optical density (OD) 405 measured using a UV-visible spectrometer (Pharmacia Ultrospec 2100 pro).
Adipogenic Differentiation Assay
Purified CD45 2 cells (passage 2) were seeded at 2 3 10 4 cells per 2-cm 2 polystyrene well. After 48 hours, the cells were subjected to adipocyte differentiation medium (ADM): a-MEM containing 10% FBS, 13 penicillin-streptomycin, 0.5 mM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 50 mM indomethacin [20] . The cells were cultured in ADM for 14 days, with medium changes every 2 days, and subjected to detection of lipid droplets accumulation by Oil Red O (Sigma-Aldrich) staining. In brief, the cells were fixed with 10% neutral buffered formalin, washed in PBS, stained with Oil Red O staining solution (3 parts Oil Red O stock solution and 2 parts PBS) for 10 minutes at room temperature, followed by washing twice with PBS. medium in a 15-ml conical centrifugation tube (BD Falcon, San Jose, CA), and subjected to centrifugation at 200g for 5 minutes at room temperature. The resultant cell pellets, together with the centrifugation tube and differentiation medium, were moved to a humidified CO 2 incubator for 3 weeks, with medium changes every 3 days. The micromass formed was fixed with 4% paraformaldehyde, embedded with Tissue-Tek OCT (Sakura Finetek USA, Inc., Torrance, CA, http://www.sakura-americas.com), sectioned with microtone, and stained with Alcian blue (Sigma-Aldrich), which stains glycosaminoglycans in cartilage. Nuclear fast red staining (Vector Laboratory, Burlingame, CA, http://www. vectorlabs.com) was also performed to stain the nucleus.
Chondrogenic Differentiation Assay
Transplantation of Population 1 Cells to Calvarial Bone Defects
All experiments were performed in accordance with the Stanford University Animal Care and Use Committee guidelines (protocol ID no. 9999). Female athymic CD-1 nude mice (Charles River Laboratories), aged 8 to 10 weeks, were housed 5 per cage in autoclaved cages with a 12-hour light/dark cycle and provided standard food and water ad libitum. One week before calvarial defect creation, their food was changed to a diet that included Uniprim antibiotic (Harlan Laboratories, Indianapolis, IN, http:// www.harlan.com). The calvarial defect procedure was performed as previously described by Gupta et al. [21] . The population 1 (pop1) cells (from CD-1 mice), which had been cultured in our coculture system for 5 weeks without further passage (passage 0), were seeded onto hydroxyapatite-poly(lactic-coglycolic acid) (HA-PLGA) scaffolds in the complete medium as described and incubated at 5% CO 2 at 37°C for 24 hours. After creation of 4-mm (critical size) calvarial defects on the right parietal bone, the pop1 cell-seeded HA-PLGA scaffolds or control unseeded HA-PLGA scaffolds were gently washed in PBS and placed into the defect. The scalp was immediately closed with interrupted 7-0 Vicryl sutures (Ethicon, Somerville, NJ, http://www.ethicon.com), and the mice were allowed to recover, as previously described [21] . Quantitative bone analysis was performed immediately after surgery and at weeks 2, 4, 6, and 8 by microcomputed tomography (micro-CT) using the eXplore RS Micro-CT system (GE Healthcare, Little Chalfont, U.K., http://www.gehealthcare.com) at 45 mm resolution. The Student t test was used for statistical analysis, and p values , .05 were considered statistically significant. Three-dimensional micro-CT images were reconstructed using native software, and the defect size was quantified using Adobe Photoshop CS6 (Adobe).
RESULTS
Production of Putative Stem Cells and Progenitor Cells From the Coculture System
We designed a coculture system (Fig. 1A) based on AML12 cells, a mouse hepatic cell line [17] . AML12 cells were chosen because of their ability to function as feeder cells for stem cell maintenance in vitro [22] [23] [24] . Using a 1.063 density barrier, the nucleated cell fraction, termed the "heavy fraction" (HF), was isolated from the peripheral blood of FVB-L2G mice. These mice expressed a fusion protein of luciferase and GFP in all cells. The HF was seeded on Transwell inserts at a density of 1-1.5 3 10 5 cells per cm 2 and cocultured with mitomycin C-treated AML12 cells in a system in which both groups were separated (Fig. 1A) . When no AML12 cells were seeded as a control, very few or no cells appeared on the Transwell inserts (Fig. 1B1 ) during the course of the experiment. However, in the presence of AML12 cells, many cells appeared on every Transwell insert after 1-2 weeks of incubation, indicating the supportive effect from the AML12 cells. The cells on the Transwell inserts included small star-shaped cells and round cells (Fig. 1B2, 1B3 ). Unexpectedly, relatively large fibroblast-like cells were found on some of the Transwell inserts in the presence of AML12 cells (Fig. 1B2) . Transwell inserts with these fibroblastic cells, among the other cells, were termed the population 1 group or pop1 group. Transwell inserts that did not have fibroblastic cells (Fig. 1B3) were termed the population 2 group or pop2 group. The green fluorescence of these cells demonstrated that they were all derived from the peripheral blood of FVB-L2G mice rather than from the AML12 cells, which do not express GFP ( Fig. 1B4) . The fibroblastic cells of the pop1 group (Fig.  1B2) quickly proliferated, resulting in confluence in another 2 weeks. The morphology and highly proliferative nature of these fibroblastic cells are reminiscent of the properties of stromal stem cells.
Repair of Calvarial Bone Defects
To evaluate the regenerative capability of the cells in the pop1 group, the highly reproducible in vivo critical-sized calvarial bone defect model was used [2, 21, 25] . One half of 1 million cells were seeded onto a HA-PLGA scaffold. The cell-seeded scaffolds were transplanted into a 4-mm diameter (critical-sized) defect in parietal calvarial bone. Untreated, calvarial bone defects of this size will not heal. Bone regeneration was quantified using micro-CT over the course of 8 weeks (Fig. 2A) . As shown in Figure 2B , defects treated with pop1 cell-seeded scaffolds healed at a faster rate than those treated with unseeded control scaffolds. This was evident as early as 4 weeks, with 33.76% healing with the pop1 cell-treated calvarial defects versus 9.47% in the controls (p , .05). At 6 weeks, defects treated with pop1 cells had 59.41% osteogenesis compared with 14.68% in those treated with scaffold alone (p , .05). This trend continued through week 8, when healing was found to be 69.65% in pop1 cell-seeded scaffolds and 14.94% in unseeded control scaffolds (p , .05). Therefore, treatment with pop1 cells significantly increased osteogenesis and bone regeneration in critical-sized calvarial defects.
Osteogenic Differentiation Potential of CD45
2 Cells
Knowing that multiple cell types exist in pop1, we next questioned which subset is responsible for repairing the calvarial bone defects. We first determined the surface marker profile of the pop1 cells with flow cytometry. As shown in Figure 3A , a population of CD45 + cells was identified. This finding was expected, because CD45 is a surface marker associated with all hematopoietic cells, except red blood cells and platelets. Importantly, a population of potentially nonhematopoietic cells that were negative or weakly positive for CD45 expression was also found (Fig. 3A) . To determine which population of cells was responsible for healing the calvarial defects, we tested the in vitro osteogenic differentiation activity of CD45 2 and CD45 + cells. This activity represents a unique property of osteoblasts (committed bone precursor cells): cellular mineralization (mostly calcification) in response to differentiation signals such as b-glycerol phosphate [18] . The calcium deposit can be stained with alizarin red S and quantified at OD 405 , which has a linear range between 0 and 2.5 [26] . CD45 2 cells were purified to near homogeneity from pop1 at passage 2 and subjected to differentiation induction by ODM. As shown in Figure 4A1 , a high level of matrix calcification with purified CD45 2 cells was observed. Therefore, the CD45 2 cells have the intrinsic capability of osteogenic differentiation. We next determined the contribution of CD45 2 cells to the overall calcification activity of the pop1 cells. Pop1 cells were fractionated by MACS into 2 groups of cells containing different proportions of CD45 2 cells. One group contained 19% CD45 2 cells (Fig. 4B2,   4B3 ) and the other contained 60% CD45 2 cells (Fig. 4B5, 4B6 ).
Equal amounts (6.7 3 10 4 ) of cells from each group were seeded, and an in vitro osteogenic differentiation assay was performed (Fig. 4B1, 4B4 ). As shown in Figure 4C, 
Surface Marker Profile of CD45 2 Cells
To establish the identity of the CD45 2 cells isolated from pop1, we examined their morphology and surface marker profile. As shown in Figure 5A , the purified CD45 2 cells displayed a multipole fibroblastic morphology, implicating a stromal cell phenotype. The CD45 2 fibroblastic cells were all positive for Sca-1, a surface marker frequently associated with stem and progenitor cells [27] . The CD45 2 cells were further analyzed using flow cytometry for the expression of surface markers Lin (major hematopoietic cell Li, Huang, Wu et al.
lineages markers, including CD11b, CD3e, CD45R/B220, TER-119 and Ly-6G/Ly-6c), CD19, c-kit, CD34, CD90.1, CD73, CD105, CD44, CD29, CD140a, and CD106. As shown in Figure 5B , the CD45 2 cells were negative for Lin and CD19. They were also negative for c-kit and CD34, markers associated with hematopoietic stem cells. However, the CD45 2 cells were positive for CD90.1, CD73, CD105, CD44, CD29, CD140a, and CD106. Taken together, the CD45 2 cells are a population of nonhematopoietic cells. The expression of CD105, CD73, and CD90 and the lack of expression of CD45, CD34, CD11b, and CD19 are among the minimal criteria for multipotent MSCs, as defined by the ISCT [28] . Moreover, the expression of CD44, CD106, and CD140a was previously reported for bone marrow-derived MSCs [29] [30] [31] [32] (Table 1) . Therefore, these CD45 2 fibroblast-like cells have the surface marker profile of MSCs and are very likely a type of mesenchymal stem cell.
Trilineage Differentiation
According to the ISCT, cells defined as MSCs are capable of trilineage differentiation (i.e., osteogenic, adipogenic, and chondrogenic). We first demonstrated the osteogenic differentiation capability of our CD45 2 cells (Fig. 4) . We next examined their capabilities for chondrogenic and adipogenic differentiation. As shown in Figure 6A , when the purified CD45 2 cells were subjected to chondrocyte differentiation medium, a micromass was found that stained positively with Alcian blue, which stains glycosaminoglycans, indicating chondrogenic differentiation [20] . When the cells were subjected to adipocyte differentiation medium, oil droplets inside the cells were observed that stained positively with Oil Red O (Fig. 6B) , indicating adipogenic differentiation [20] . Therefore, together with the osteogenic differentiation capability shown in Figure 4 , these CD45 2 fibroblastic cells possess the capability of trilineage differentiation. These data support the conclusion that the fibroblastic CD45 2 cells fulfill the minimal criteria of MSC definition proposed by the ISCT. In view of their peripheral blood origin, we named the cells, blood-derived mesenchymal stem cells or BD-MSCs.
DISCUSSION
Stomal cells capable of repairing critical-sized bone defects have previously been isolated from bone marrow [1] and adipose tissue [2] . These cells are isolated using invasive procedures, such as bone marrow aspiration and liposuction. Cells with similar potential, but retrieved from peripheral blood, will provide an advantageous alternative source owing to their ease of retrieval. Circulating cells with intrinsic osteogenic function have been described in other models. Kuznetsov et al. [14] reported that transplantation of circulating skeletal stem cells to the subcutaneous pockets of mice resulted in bone formation, indicating intrinsic osteogenic differentiation potential. Wan et al. [16] reported that a group of undefined allogeneic peripheral blood-derived MSClike cells improved healing of critical-sized ulna bone defects in rabbits. We have extended these previous findings and demonstrated that a population of mouse peripheral blood-derived cells isolated and expanded by our coculture system, termed pop1 cells, can enhance healing of mouse calvarial bone defects. Ulna bone formation and calvarial bone formation represent the two major bone formation modes: endochondral ossification and intramembranous ossification, respectively [33, 34] . The present study has thus provided a proof of principle of treating bone defects with peripheral blood-derived cells. We have further discovered that, among pop1 cells, the most plausible candidate cell responsible for healing the critical-sized calvarial defects is a group of CD45 2 fibroblastic cells. These are the cells predominantly responsible for the calcification activity of pop1 cells. Calcification activity is unique to osteoblasts and also is an essential process during bone formation [18] . We eventually identified the CD45 2 fibroblastic cells as a type of MSCs, named BD-MSCs, on the basis of their surface marker profile and their trilineage differentiation potential, as defined by the ISCT. BD-MSCs differ from the circulating skeletal stem cells described by Kuznetsov et al. [14] because the latter do not express CD105, a critical surface marker for MSC determination. In contrast, Wan et al. [16] described a group of peripheral blood-derived cells capable of healing rabbit critical-sized ulna bone defects as MSCs. However, BD-MSCs cannot be compared with those cells because the surface marker profile for the latter is not available.
Many reports and reviews have discussed MSCs in peripheral blood using various animal models [7, [9] [10] [11] 35] . However, because of the lack of a standard set of criteria for MSC definition in most reports, a conclusive comparison between BD-MSCs and previously described cells is impractical. The ISCT has defined a set of minimal criteria to address this issue for human MSCs [28] . According to the ISCT, human MSCs must fulfill these minimal criteria: they must be plastic adherent, express surface markers CD105, CD73, and CD90 and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19, and human leukocyte antigen-DR (for human cells), and be capable of differentiation toward osteoblasts, adipocytes, and chondrocytes. BD-MSCs, although derived from mouse peripheral blood, fulfill these criteria defined for human MSCs. However, the surface marker profiles or differentiation phenotypes of previously described peripheral blood MSCs only partially fulfilled [14, 16, [36] [37] [38] [39] [40] [41] [42] [43] or, in some studies, deviated from the ISCT criteria [44] . Therefore, determining whether BD-MSCs and these previously reported cells are related is not possible. Because of reproducibility issues [45] [46] [47] , the existence of MSCs in the peripheral blood is still questioned. From this perspective, BD-MSCs provide new evidence that MSCs, as defined by the ISCT, can be cultured and expanded from the peripheral blood.
The question of whether BD-MSCs exist in the circulation or are a result of our unique coculture condition is important. In order to answer this question, freshly isolated peripheral blood cells were subjected to flow cytometry to examine cells that simultaneously express the characteristic BD-MSC surface markers (CD45 Fig. 2) , which is too rare to prove existence. Thus, the existence of circulating BD-MSCs cannot be fully demonstrated. The BD-MSCs might exist in the circulation in very low numbers or be the result of cultivation of origin cells of BDMSCs, which do not express all the characteristic BD-MSC surface markers, in the circulation with our unique culture conditions.
A key to the successful culture of BD-MSCs from the peripheral blood is our coculture system, in which nonreplicating hepatic lineage (AML12) cells were present as feeder cells. AML12 cells were used because hepatic cells are known to produce the cytokines frequently used for stem cell culture [22] [23] [24] . Without the presence of AML12 cells, few or no cells appeared on the Transwell inserts (Fig. 1B1) . In the presence of AML12 cells, vigorous cell proliferation on the Transwell inserts was observed (Fig. 1B2, 1B3) , indicating that the factors secreted from AML12 cells facilitated proliferation of the peripheral blood-derived cells. However, even with the support of AML12 cells, our current coculture system produces BD-MSCs in 1-4 of the Transwell inserts in a 6-well format seeded with 2.9 3 10 6 nucleated HF cells. This frequency is low but comparable to MSCs obtained from the bone marrow (1 from 10 6 nucleated bone marrow cells) [35] . Nevertheless, this frequency might not reflect their in vivo abundance, because it is condition dependent. For example, we have observed that serum starvation of AML12 cells can increase BD-MSC culture frequency more than four times from age-and sex-matched mice (data not shown). Therefore, our current coculture system is likely not the most optimized growth condition. Identification of AML12-released factors that facilitate cell proliferation might be the key to enhancing BD-MSC isolation. Transforming growth factor-a, insulinlike growth factor 1, hepatocyte growth factor, and vascular endothelial growth factor, four well-recognized cytokines produced by hepatocytes, were individually tested and were insufficient to stimulate proliferation of peripheral blood cells (data not shown). Interestingly, although the heavy fraction cells can be stimulated to produce BD-MSCs in our coculture system, freshly isolated CD45 Recently Guihard et al. [48] reported that activated monocytes/macrophages (isolated as CD14 + cells) greatly stimulated the calcification activity of bone marrow-derived MSCs through oncostatin M signaling. Nicolaidou et al. [49] also reported that monocytes promote MSC osteoblast formation through activating signal transducer and activator of transcription 3, a positive feedback regulator for oncostatin M signaling. These findings suggest that during the bone healing process, the osteogenic differentiation activity of MSCs is regulated by other cells. We have demonstrated that cells from pop1, a mixture of BDMSCs and CD45 + cells, can heal critical-sized calvarial defects. BD-MSCs are the predominant cells responsible for pop1 cells' calcification activity. However, the roles of the CD45 + cells, which are mostly CD14 + (data not shown), remain to be determined. Moreover, greater analysis of pop1 cells and BD-MSC cells in other MSC functional assays, such as ectopic bone organ formation [50] , will be important to determine the specific functions of distinct MSC cell populations. Future studies on the interactions between BD-MSCs and cells in the bone wound will also provide valuable insights into the mechanisms underlying enhanced bone healing. An understanding of these mechanisms might result in the development of BD-MSC-based cell therapy to enhance bone repair.
CONCLUSION
We present a novel technique to isolate a population of cells derived from peripheral blood that enhance healing of calvarial bone defects. The BD-MSC is the most probable candidate cell responsible for the improved healing owing to its high cell calcification activity in response to osteogenic differentiation. BD-MSCs, which fulfill the MSC criteria as defined by the ISCT, provide new evidence that MSCs can be isolated and expanded from peripheral blood. The BD-MSC is an ideal cell type for the development of cell-based therapy to enhance bone repair. Figure 1A ).
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